Latest Conference Articles

May 15th 2013, 2:00pm

ASCO Annual Meeting

Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.

May 15th 2013, 6:07am

ASCO Annual Meeting

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

May 6th 2013, 4:05pm

AUA Annual Meeting

An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.

May 6th 2013, 2:18pm

AUA Annual Meeting

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

May 6th 2013, 5:34am

AUA Annual Meeting

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

May 5th 2013, 3:52pm

AUA Annual Meeting

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

April 16th 2013, 5:29am

AUA Annual Meeting

The 108th American Urological Association (AUA) Annual Meeting is being held at the San Diego Convention Center from May 4 - 8, 2013, and features research, guideline updates, and the latest advances in urologic medicine.

March 18th 2013, 2:10pm

Interdisciplinary Prostate Cancer Congress

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

March 18th 2013, 1:16pm

Interdisciplinary Prostate Cancer Congress

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

March 18th 2013, 12:59pm

Interdisciplinary Prostate Cancer Congress

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

March 18th 2013, 6:56am

Interdisciplinary Prostate Cancer Congress

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

March 14th 2013, 11:54am

PER® Miami Breast Cancer Conference

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

March 9th 2013, 4:10pm

PER® Miami Breast Cancer Conference

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.

March 9th 2013, 4:10pm

PER® Miami Breast Cancer Conference

Physicians wondering how the Affordable Care Act (ACA) will impact their practices heard a robust defense of the new law from Donna E. Shalala, PhD, on Saturday.

March 9th 2013, 2:16pm

PER® Miami Breast Cancer Conference

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.

March 9th 2013, 2:05pm

PER® Miami Breast Cancer Conference

As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.

March 8th 2013, 1:50pm

PER® Miami Breast Cancer Conference

Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.

March 8th 2013, 1:46pm

PER® Miami Breast Cancer Conference

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

March 8th 2013, 12:26pm

PER® Miami Breast Cancer Conference

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

March 8th 2013, 8:54am

PER® Miami Breast Cancer Conference

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.